Back

Acne vulgaris market projected to grow through 2036 amid emerging therapies

Verifying
  • DelveInsight published a report on the acne vulgaris treatment market through 2036.
  • The United States held the largest market share among the leading markets in 2025.
  • Sagimet’s AURORA Phase 3 denifanstat trial remains scheduled to begin enrollment in fourth-quarter 2026.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.